Dermatology Specialists Research

Clinical Dermatology Trials

  • Who We Are
    • About
    • Meet Our President/CEO
    • Meet Our Doctors
    • Meet Our Staff
  • Facilities
    • DS Research of Kentucky
    • DS Research of Southern Indiana
    • Travel Accommodations
  • Research Studies
    • ACD Study
    • Other Enrolling Studies
  • Sponsor/CRO
  • News
  • Contact

Introduction to Shared Decision-Making in Eczema Treatment

August 10, 2023 by admin

Eczema, a chronic skin condition, often requires a unique and personalized approach to treatment. It’s not just about finding the right medication or therapy; it’s about building a relationship between healthcare providers (HCPs) and patients. This relationship, founded on trust, empathy, and collaboration, is at the heart of shared decision-making (SDM) – a process that has become increasingly vital in the management of eczema.

SDM involves patients, caregivers, and HCPs working together to make informed decisions about treatments and care plans, ensuring that the chosen path aligns with the patient’s needs, preferences, and lifestyle. In June 2023, the National Eczema Association (NEA) published a paper on this subject, shedding light on the essential elements of SDM in eczema treatment.

This research, conducted through a survey of the patient and caregiver community, offers valuable insights into what makes SDM effective and why it’s so crucial for those living with eczema. In this blog post, we’ll explore the key findings of the NEA’s research and delve into the importance of shared decision-making in the journey toward better eczema care.

Overview of the National Eczema Association’s Findings on SDM

The National Eczema Association (NEA) embarked on a mission to understand the dynamics of shared decision-making (SDM) in the context of eczema treatment. Recognizing the importance of collaboration between patients, caregivers, and healthcare providers (HCPs), the NEA conducted a survey in early 2021 to gauge the experiences, preferences, and motivators for SDM within its patient and caregiver community.

The survey reached 840 respondents, asking them to rate various factors related to SDM on a scale from 0 (not important at all) to 4 (absolutely essential). These factors encompassed aspects about the HCP, the patient, the visit, and the guidance provided. Respondents were considered to have their โ€œneeds metโ€ if they indicated a factor was very important or absolutely essential and also reported it as usually or always true.

The findings were revealing. For the 9 factors deemed very important or absolutely essential by at least 80% of respondents, the percentage of those who felt their needs were not met ranged from 11.4% to 36.3%. The study uncovered that eczema patients and caregivers want to be actively involved in decision-making for their treatments. Moreover, SDM is more likely to be facilitated when patient education and empowerment are combined with HCPs who initiate treatment discussions and are compassionate listeners to patient perspectives.

Overall, the NEA’s research offers a comprehensive look into the multifaceted nature of SDM in eczema care. It emphasizes the need for a collaborative approach where both patients and providers are engaged, informed, and aligned in their goals. The insights derived from this study not only shed light on the current state of SDM in eczema treatment but also pave the way for enhancing patient-provider relationships and improving treatment outcomes.

Final Thoughts on Shared Decision-Making in Eczema Care

In the complex landscape of eczema treatment, shared decision-making (SDM) emerges as a vital component in fostering successful patient-provider relationships. The recent research conducted by the National Eczema Association (NEA) illuminates the essential elements that make SDM effective and underscores the importance of trust, empathy, collaboration, and patient empowerment. By embracing these principles, healthcare providers, patients, and caregivers can work together to create personalized care plans that align with individual needs and preferences. The insights from this study offer a roadmap for enhancing the quality of eczema care and highlight the potential for SDM to transform the way we approach chronic conditions.

Explore the Original Article on Shared Decision-Making

For those interested in delving deeper into this subject, the original article titled “Breaking Down the Essential Elements of Shared Decision-Making” by Lauren Hewett, published in June 2023, offers a comprehensive look at the NEA’s research. It provides detailed findings, analysis, and context that can further inform healthcare professionals, patients, and caregivers about the importance of SDM in eczema treatment. You can read the full article here: (https://www.hmpgloballearningnetwork.com/site/thederm/nea-approved-features/breaking-down-essential-elements-shared-decision-making).

By understanding and implementing the principles of shared decision-making, we can take a significant step towards a more compassionate, personalized, and effective approach to eczema care. It’s not just about choosing the right treatment; it’s about building a relationship that empowers patients and enhances their quality of life.

Dermatology

Contact Us

DS Research of Kentucky
3810 Springhurst Blvd.
Suite 130
Louisville, KY 40241
O: 502.585.9059
F: 502.585.9708

DS Research of Southern Indiana
1005 E. Lewis & Clark Pkwy
Clarksville, IN 47129
O: 812.213.9769
F: 812.214.7405

Interested About Coming To Us? Our doctors are ready to see you now.

  • This field is for validation purposes and should be left unchanged.

dsresearchtrials

Attention those with vitiligo! Ever experience mo Attention those with vitiligo!

Ever experience more bleeding and bruising after using a vitiligo treatment?

Weโ€™re looking to change that.

Weโ€™re working on a new investigational medication that may minimize common side effects
you might see in treatments on the market.

We currently have PAID vitiligo studies open at both our Kentucky and Southern Indiana locations! ๐Ÿคฉ

Also, donโ€™t forget about our patient referral program! ๐Ÿ’ฐ Refer us someone who might qualify for one of our studies and receive a $25 gift card ๐Ÿ˜
Attention those with vitiligo! Ever experience mo Attention those with vitiligo!

Ever experience more bleeding and bruising after using a vitiligo treatment?

Weโ€™re looking to change that.

Weโ€™re working on a new investigational medication that may minimize common side effects
you might see in treatments on the market.

We currently have vitiligo studies open at both our Kentucky and Southern Indiana locations! ๐Ÿคฉ If you are interested or have any questions please give us a call. ๐Ÿ“ž 

Also, donโ€™t forget about our patient referral program! ๐Ÿ’ฐ Refer us someone who might qualify for one of our studies and receive a $25 gift card ๐Ÿ˜
๐“๐ž๐š๐ฆ ๐Œ๐ž๐ฆ๐›๐ž๐ซ ๐“๐ฎ ๐“๐ž๐š๐ฆ ๐Œ๐ž๐ฆ๐›๐ž๐ซ ๐“๐ฎ๐ž๐ฌ๐๐š๐ฒ! โœจ

๐™ผ๐šŽ๐šŽ๐š ๐š‚๐šŠ๐š›๐šŠ๐š‘, ๐š˜๐šž๐š› ๐š—๐šŽ๐š ๐šŽ๐šœ๐š ๐™ฒ๐š•๐š’๐š—๐š’๐šŒ๐šŠ๐š• ๐š๐šŽ๐šœ๐šŽ๐šŠ๐š›๐šŒ๐š‘ ๐™ฒ๐š˜๐š˜๐š›๐š๐š’๐š—๐šŠ๐š๐š˜๐š›. ๐š†๐šŽ ๐šŠ๐š›๐šŽ ๐šœ๐š˜ ๐šŽ๐šก๐šŒ๐š’๐š๐šŽ๐š ๐šŠ๐š—๐š ๐š•๐šž๐šŒ๐š”๐šข ๐š๐š˜ ๐š‘๐šŠ๐šŸ๐šŽ ๐š‘๐šŽ๐š› ๐Ÿคฉ

#research #dermatology #dermatologyresearch #clinicalresearch #clinicaltrials #teammembertuesday #dermatologist #clinicalresearchcoordinator #alopecia #warts #atopicdermatitis #psoriasis #hs #hidradenitissuppurativa #alopeciaareata #hairloss
๐™„๐™ฉโ€™๐™จ ๐™–๐™ก๐™ก ๐™ž๐™ฃ ๐™ฉ๐™๐™š ๐™„๐™ฉโ€™๐™จ ๐™–๐™ก๐™ก ๐™ž๐™ฃ ๐™ฉ๐™๐™š โœจ๐™™๐™š๐™ฉ๐™–๐™ž๐™ก๐™จโœจ

๐™ƒ๐™–๐™ซ๐™š ๐™ฎ๐™ค๐™ช ๐™จ๐™š๐™š๐™ฃ ๐™ค๐™ช๐™ง ๐™Ž๐™ค๐™ช๐™ฉ๐™๐™š๐™ง๐™ฃ ๐™„๐™‰ ๐™ก๐™ค๐™˜๐™–๐™ฉ๐™ž๐™ค๐™ฃ ๐™ฎ๐™š๐™ฉ? 

๐˜พ๐™ค๐™ข๐™š ๐™จ๐™š๐™š ๐™ช๐™จ ๐™ค๐™ง ๐™œ๐™ž๐™ซ๐™š ๐™ช๐™จ ๐™– ๐™˜๐™–๐™ก๐™ก ๐™ฉ๐™ค ๐™ก๐™š๐™–๐™ง๐™ฃ ๐™ข๐™ค๐™ง๐™š ๐™–๐™—๐™ค๐™ช๐™ฉ ๐™ฉ๐™๐™š ๐™˜๐™ช๐™ง๐™ง๐™š๐™ฃ๐™ฉ ๐™ฅ๐™–๐™ž๐™™ ๐™˜๐™ก๐™ž๐™ฃ๐™ž๐™˜๐™–๐™ก ๐™ฉ๐™ง๐™ž๐™–๐™ก๐™จ ๐™ฌ๐™š ๐™๐™–๐™ซ๐™š ๐™ค๐™ฅ๐™š๐™ฃ!

๐Ÿ“๐—ž๐—ฒ๐—ป๐˜๐˜‚๐—ฐ๐—ธ๐˜†: ๐Ÿฑ๐Ÿฌ๐Ÿฎ-๐Ÿฑ๐Ÿต๐Ÿฑ-๐Ÿต๐Ÿฌ๐Ÿฑ๐Ÿต
๐Ÿ“๐—ฆ๐—ผ๐˜‚๐˜๐—ต๐—ฒ๐—ฟ๐—ป ๐—œ๐—ก: ๐Ÿด๐Ÿญ๐Ÿฎ-๐Ÿฎ๐Ÿญ๐Ÿฏ-๐Ÿต๐Ÿณ๐Ÿฒ๐Ÿต
Load More... Follow on Instagram

Copyright © 2025 Dermatology Specialists Research :: Clinical Dermatology Trials

Privacy Policy
  • Facebook
  • Instagram
  • LinkedIn